Effect of ganciclovir on murine cytomegalovirus-induced reactivation of toxoplasma pneumonia

Sharon Banister, Claire Pomeroy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Active cytomegalovirus (CMV) infection induces immunosuppression and predisposes to the development of life-threatening superinfections in immunocompromised patients. We have described a mouse model in which acute murine CMV (MCMV) infection reactivates previously dormant Toxoplasma gondii infection, manifested as pneumonia. To determine whether therapy with ganciclovir might prevent MCMV-induced reactivation of T. gondii pneumonia, we administered ganciclovir to mice starting 1 day before to 2 days after MCMV infection and continuing for 14 days. When ganciclovir was begun early (before, on the day of, or 1 day after MCMV infection), the severity of T. gondii pneumonia reactivated by MCMV was significantly reduced. However, when therapy was delayed, no beneficial effect of ganciclovir was observed and the severity of MCMV-induced reactivation of T. gondii pneumonia was comparable to that seen in untreated animals. We conclude that ganciclovir therapy can attenuate but not eliminate MCMV-induced reactivation of T. gondii pneumonia and that prophylactic or very early administration of the drug is necessary to achieve protection.

Original languageEnglish (US)
Pages (from-to)576-580
Number of pages5
JournalThe Journal of Laboratory and Clinical Medicine
Volume122
Issue number5
StatePublished - 1993
Externally publishedYes

Fingerprint

Muromegalovirus
Ganciclovir
Toxoplasma
Pneumonia
Toxoplasmosis
Cytomegalovirus Infections
Superinfection
Immunocompromised Host
Immunosuppression
Animals
Therapeutics
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Effect of ganciclovir on murine cytomegalovirus-induced reactivation of toxoplasma pneumonia. / Banister, Sharon; Pomeroy, Claire.

In: The Journal of Laboratory and Clinical Medicine, Vol. 122, No. 5, 1993, p. 576-580.

Research output: Contribution to journalArticle

@article{1038b8ab765e4c89b40d08c5c82bd5e3,
title = "Effect of ganciclovir on murine cytomegalovirus-induced reactivation of toxoplasma pneumonia",
abstract = "Active cytomegalovirus (CMV) infection induces immunosuppression and predisposes to the development of life-threatening superinfections in immunocompromised patients. We have described a mouse model in which acute murine CMV (MCMV) infection reactivates previously dormant Toxoplasma gondii infection, manifested as pneumonia. To determine whether therapy with ganciclovir might prevent MCMV-induced reactivation of T. gondii pneumonia, we administered ganciclovir to mice starting 1 day before to 2 days after MCMV infection and continuing for 14 days. When ganciclovir was begun early (before, on the day of, or 1 day after MCMV infection), the severity of T. gondii pneumonia reactivated by MCMV was significantly reduced. However, when therapy was delayed, no beneficial effect of ganciclovir was observed and the severity of MCMV-induced reactivation of T. gondii pneumonia was comparable to that seen in untreated animals. We conclude that ganciclovir therapy can attenuate but not eliminate MCMV-induced reactivation of T. gondii pneumonia and that prophylactic or very early administration of the drug is necessary to achieve protection.",
author = "Sharon Banister and Claire Pomeroy",
year = "1993",
language = "English (US)",
volume = "122",
pages = "576--580",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Effect of ganciclovir on murine cytomegalovirus-induced reactivation of toxoplasma pneumonia

AU - Banister, Sharon

AU - Pomeroy, Claire

PY - 1993

Y1 - 1993

N2 - Active cytomegalovirus (CMV) infection induces immunosuppression and predisposes to the development of life-threatening superinfections in immunocompromised patients. We have described a mouse model in which acute murine CMV (MCMV) infection reactivates previously dormant Toxoplasma gondii infection, manifested as pneumonia. To determine whether therapy with ganciclovir might prevent MCMV-induced reactivation of T. gondii pneumonia, we administered ganciclovir to mice starting 1 day before to 2 days after MCMV infection and continuing for 14 days. When ganciclovir was begun early (before, on the day of, or 1 day after MCMV infection), the severity of T. gondii pneumonia reactivated by MCMV was significantly reduced. However, when therapy was delayed, no beneficial effect of ganciclovir was observed and the severity of MCMV-induced reactivation of T. gondii pneumonia was comparable to that seen in untreated animals. We conclude that ganciclovir therapy can attenuate but not eliminate MCMV-induced reactivation of T. gondii pneumonia and that prophylactic or very early administration of the drug is necessary to achieve protection.

AB - Active cytomegalovirus (CMV) infection induces immunosuppression and predisposes to the development of life-threatening superinfections in immunocompromised patients. We have described a mouse model in which acute murine CMV (MCMV) infection reactivates previously dormant Toxoplasma gondii infection, manifested as pneumonia. To determine whether therapy with ganciclovir might prevent MCMV-induced reactivation of T. gondii pneumonia, we administered ganciclovir to mice starting 1 day before to 2 days after MCMV infection and continuing for 14 days. When ganciclovir was begun early (before, on the day of, or 1 day after MCMV infection), the severity of T. gondii pneumonia reactivated by MCMV was significantly reduced. However, when therapy was delayed, no beneficial effect of ganciclovir was observed and the severity of MCMV-induced reactivation of T. gondii pneumonia was comparable to that seen in untreated animals. We conclude that ganciclovir therapy can attenuate but not eliminate MCMV-induced reactivation of T. gondii pneumonia and that prophylactic or very early administration of the drug is necessary to achieve protection.

UR - http://www.scopus.com/inward/record.url?scp=0027422583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027422583&partnerID=8YFLogxK

M3 - Article

VL - 122

SP - 576

EP - 580

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 5

ER -